---
schema_version: "secwatch.filing_event.v1"
accession: "0001699031-25-000189"
form_type: "8-K"
ticker: "GRAL"
cik: "0001699031"
company_name: "GRAIL, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:18:37.473021+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GRAIL Q3 revenue $36.2M (+26% YoY); U.S. Galleri revenue $32.6M (+28%)

## Summary
- Net loss $89.0M, improving 29% YoY; adjusted EBITDA $(71.7)M.
- Galleri tests sold >45,000, up 39% YoY; PMA submission to FDA expected Q1 2026.
- Cash $547.1M at Sep 30; pro forma >$850M after private placement.
- Non-GAAP adjusted gross profit $20.0M (+69% YoY); gross loss $13.7M.

## SEC filing metadata
- accession: 0001699031-25-000189
- form_type: 8-K
- ticker: GRAL
- cik: 0001699031
- company_name: GRAIL, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699031/000169903125000189/0001699031-25-000189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699031/000169903125000189/gral-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001699031-25-000189
- JSON: https://secwatch.observer/filing/0001699031-25-000189.json
- Plain text: https://secwatch.observer/filing/0001699031-25-000189.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.